{"product_id":"plx-business-model-canvas","title":"(PLX) Protalix BioTherapeutics, Inc. Business Model Canvas Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtalix BioTherapeutics Business Model Canvas in One Snapshot\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full Business Model Canvas for Protalix BioTherapeutics, Inc. to see how this biopharma company creates value through its proprietary technologies, strategic partnerships, and focused revenue model. This clear, company-specific snapshot helps you understand the key drivers behind its growth and competitive position. Download the full version to accelerate your research or investment analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePartnerships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer commercialization alliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePfizer remains Protalix BioTherapeutics, Inc.’s key commercialization ally, helping sell and access enzyme therapies in selected territories beyond Protalix’s own sales reach. The alliance has supported Protalix for years and helps convert a small internal footprint into broader market coverage, with Protalix reporting 2025 revenue of about $44.1 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChiesi Farmaceutici S.p.A. Fabry partner\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChiesi Farmaceutici S.p.A. is Protalix BioTherapeutics, Inc.’s core Fabry partner for PRX-102, also called Elfabrio, the 1 mg\/kg every-2-weeks therapy approved in the US in 2023 and in Europe in 2022. The alliance covers development, regulatory work, and launch planning, and it is the main path to rare-disease revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFiocruz Brazil collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFiocruz gives Protalix a gateway into Brazil’s government-linked public health system, which serves about 203 million people, so the tie-up matters for broad access and local credibility. It also supports Protalix’s international commercialization model by pairing a rare-disease drug maker with a trusted public-sector partner in one of Latin America’s largest healthcare markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProCellEx suppliers and CMO network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProCellEx suppliers and the CMO network give Protalix BioTherapeutics, Inc. access to plant-cell media, purification, fill-finish, and QC services that keep biologics output moving. These links are critical for supply reliability and scale, especially for its single-use, outsourced manufacturing model.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSecures key biologics inputs\u003c\/li\u003e\n\u003cli\u003eSupports plant-cell expression and purification\u003c\/li\u003e\n\u003cli\u003eHelps fill-finish and QC capacity\u003c\/li\u003e\n\u003cli\u003eReduces single-point supply risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinicians and rare-disease centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinicians and rare-disease centers are core partners for Protalix BioTherapeutics, Inc.: they identify eligible patients, run protocol-heavy trials, and support real-world use of therapies in Gaucher and Fabry. This network matters most in tiny populations, where Fabry affects about 1 in 40,000 to 60,000 males and Gaucher about 1 in 50,000 to 100,000 births.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrives enrollment and retention\u003c\/li\u003e\n\u003cli\u003eImproves protocol adherence\u003c\/li\u003e\n\u003cli\u003eSupports post-approval use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtalix Bets on Pfizer, Chiesi, and Fiocruz to Drive Rare-Disease Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. relies on Pfizer, Chiesi Farmaceutici S.p.A., and Fiocruz to expand reach, fund commercialization, and support rare-disease access. These partnerships matter because Protalix reported 2025 revenue of about $44.1 million, while Elfabrio remains its main partnered growth driver.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eFY2025 note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer\u003c\/td\u003e\n\u003ctd\u003eCommercial access\u003c\/td\u003e\n\u003ctd\u003eBroadens reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChiesi\u003c\/td\u003e\n\u003ctd\u003eElfabrio partner\u003c\/td\u003e\n\u003ctd\u003eMain revenue path\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiocruz\u003c\/td\u003e\n\u003ctd\u003eBrazil access\u003c\/td\u003e\n\u003ctd\u003ePublic system gateway\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, real-world Business Model Canvas for Protalix BioTherapeutics, mapping its biopharma strategy, partnerships, revenue model, and competitive edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly maps Protalix BioTherapeutics’ business model into one editable snapshot, making complex strategy easy to review and compare.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for Protalix BioTherapeutics, Inc. claims, helping investors verify assumptions fast and make more confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eActivities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecombinant protein engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix’s recombinant protein engineering is the core upstream activity that feeds its pipeline, with 4 named programs: PRX-102, PRX-110, PRX-115, and PRX-119. It designs and develops therapeutic proteins in-house, turning early protein work into clinical candidates and, in 2025, keeping the pipeline tied to one central R\u0026amp;D engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlant-cell expression development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. develops plant-cell expression through its ProCellEx platform, using carrot cells to make recombinant proteins instead of standard mammalian-cell lines. This activity sits at the center of its process control, product quality, and lower-cost manufacturing model, and it supports the company’s approved biologic platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. runs preclinical work and multi-phase programs, with PRX-102 in late-stage Fabry development and PRX-110 already through Phase IIa in cystic fibrosis. Managing two named assets across Phase IIa and late-stage testing is a key value driver because each trial readout can unlock regulatory, licensing, and revenue milestones.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing and quality operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. runs biologics manufacturing, release testing, and quality systems at its Carmiel site to keep 2 approved products, Elfabrio and Elelyso, supply-ready. These controls also support pipeline batches and help keep international deliveries stable across regulated markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 approved products\u003c\/li\u003e\n\u003cli\u003eRelease testing for every batch\u003c\/li\u003e\n\u003cli\u003eSupports global supply continuity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal commercialization and regulatory work\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. drives global commercialization by supporting product registration, market access, and partner execution for Elelyso, which is sold in 7 countries, including the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. Regulatory work stays central because each market needs local approvals, pricing, and reimbursement support.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eElelyso is marketed across 7 countries.\u003c\/li\u003e\n\u003cli\u003eRegistration and market access are ongoing.\u003c\/li\u003e\n\u003cli\u003ePartner commercialization supports local execution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtalix 2025: Two Approved Products, Four Pipeline Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. key activities center on ProCellEx-based protein engineering, clinical development, and GMP manufacturing at Carmiel. In 2025, that work supported 2 approved products, Elfabrio and Elelyso, plus late-stage and Phase II pipeline programs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2025 status\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e4 named programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e2 approved products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003ctd\u003eElelyso in 7 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the actual Protalix BioTherapeutics, Inc. Business Model Canvas you’ll receive after purchase, not a sample or mockup. What you see here is taken directly from the final document, with the same structure, formatting, and content. Once you complete your order, you’ll get full access to this exact file, ready to edit, present, or share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eResources\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProCellEx platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProCellEx is Protalix BioTherapeutics, Inc. proprietary plant cell-based protein expression system and its core asset. It underpins the companys differentiated manufacturing model and has helped support two approved therapies, Elelyso and Elfabrio, giving Protalix a rare non-mammalian production platform in a market still dominated by CHO-based systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApproved product Elelyso\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElelyso is Protalix BioTherapeutics’ FDA-approved Gaucher disease therapy, giving the Company a real commercial product, payer history, and real-world safety and efficacy data. It also validates Protalix’s plant-cell expression platform, since Elelyso has been on the market since 2012 and remains the Company’s key marketed asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLate-stage pipeline assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. key late-stage resources are 4 programs: PRX-102 is the lead Fabry asset and is already de-risked by commercialization as Elfabrio, while PRX-110, PRX-115, and PRX-119 extend the pipeline into respiratory, gout, and NETs-related diseases. These assets are the main future growth drivers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRare-disease biologics expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc.’s rare-disease biologics expertise is a core asset: it combines protein engineering, regulatory strategy, and orphan-disease development know-how that is hard to copy fast. That matters in a niche market where its lead asset, Elfabrio, is an FDA-approved therapy for Fabry disease, a rare disorder affecting about 1 in 40,000 to 60,000 males.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtein engineering is a key moat\u003c\/li\u003e\n\u003cli\u003eRegulatory know-how shortens review risk\u003c\/li\u003e\n\u003cli\u003eOrphan-disease experience is hard to replicate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner network and market rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. uses partner network and market rights as key intangible assets: its Chiesi partnership for Elfabrio extends commercial reach beyond Protalix’s own footprint and shares launch and development risk. This model matters because Protalix reported $12.8 million in total revenue in 2024, so partner-led access is central to scaling without building a full global sales force.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExtends reach through licensed market rights\u003c\/li\u003e\n\u003cli\u003eReduces need for full internal infrastructure\u003c\/li\u003e\n\u003cli\u003eShares development and launch risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtalix’s Growth Engine: ProCellEx, Approved Drugs, and Chiesi\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. key resources are its ProCellEx plant-cell platform, approved products Elelyso and Elfabrio, and rare-disease know-how. The Chiesi partnership also matters: Protalix reported $12.8 million in total revenue in 2024, so partnered reach is core to scaling.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProCellEx\u003c\/td\u003e\n\u003ctd\u003eDifferentiated biologics platform\u003c\/td\u003e\n\u003ctd\u003e2 approved therapies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner network\u003c\/td\u003e\n\u003ctd\u003eExpands reach, shares risk\u003c\/td\u003e\n\u003ctd\u003e$12.8 million revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eValue Propositions\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlant-derived recombinant biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics makes recombinant therapeutic proteins in plant cells, a non-animal, non-mammalian platform that gives it a clear technology edge. Its plant-derived biologics have reached the market in 2 approved therapies, Elelyso and Elfabrio, showing the value of a differentiated, scalable production method.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare-disease treatment focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. focuses on ultra-rare diseases like Gaucher and Fabry, where patient counts are small but unmet need is high; Fabry is estimated at about 1 in 40,000 to 60,000 people. Its marketed therapies, Elelyso and Elfabrio, give it clinical and commercial relevance in a niche with few treatment options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal access across 8-plus regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics has reached patients in at least 7 named countries, including the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey, showing broad global access across 8-plus regions. That reach helps deliver treatment to more patients and partners, while spreading demand across markets so the business is less tied to any one country.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline beyond current sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. is not tied to one drug: it had $52.5 million in 2023 revenue from Fabry therapy Elfabrio, while its pipeline still spans cystic fibrosis, gout, and NETs-related diseases. That mix gives it several shots at future approvals beyond current sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFabry: commercial base today\u003c\/li\u003e\n\u003cli\u003eCF, gout, NETs: next programs\u003c\/li\u003e\n\u003cli\u003eMultiple shots at future revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-enabled commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartner-enabled commercialization lets Protalix BioTherapeutics, Inc. use alliances to speed development and widen market access. Partners add scale, local reach, and sales execution, which matters in rare disease where patient pools are small and launch costs are high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpeeds market entry\u003c\/li\u003e\n\u003cli\u003eAdds regional expertise\u003c\/li\u003e\n\u003cli\u003eImproves rare-disease reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtalix: Plant-Cell Biotech With Marketed Rare-Disease Drugs and Real Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics offers a rare mix of non-mammalian plant-cell manufacturing, approved ultra-rare disease drugs, and partner-led reach. Its lead value is proven commercialization: Elelyso and Elfabrio are marketed, and Elfabrio generated $52.5 million in 2023 revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eValue point\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform\u003c\/td\u003e\n\u003ctd\u003ePlant-cell recombinant proteins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed drugs\u003c\/td\u003e\n\u003ctd\u003eElelyso, Elfabrio\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElfabrio revenue\u003c\/td\u003e\n\u003ctd\u003e$52.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReach\u003c\/td\u003e\n\u003ctd\u003e7+ named countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Relationships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-term alliance management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. leans on long-term pharma ties, mainly licensing, development, and commercialization deals, so alliance management is a core customer relationship. Its latest reported collaboration revenue was driven largely by the Chiesi partnership for Elfabrio, showing how ongoing coordination, milestone tracking, and partner execution feed Company Name cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical affairs support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics supports physicians, clinics, and treatment centers with product and disease guidance so specialist teams can use therapies correctly in rare diseases, where care gaps can quickly disrupt treatment continuity.\u003c\/p\u003e\n\u003cp\u003eThis medical affairs support helps providers make informed decisions on patient selection, dosing, and follow-up for Protalix BioTherapeutics' enzyme therapies, including Elfabrio for Fabry disease and Elelyso for Gaucher disease.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and market-access collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. works with payers, governments, and health authorities to secure reimbursement and public-sector adoption for orphan drugs like Elfabrio, which the FDA approved in 2023. In international markets, country-by-country pricing and market-access talks can decide whether patients actually get treated, so this relationship is a core sales driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePharmacovigilance and post-market oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. must track safety for its 2 approved therapies, ELELYSO and ELFABRIO, through ongoing adverse-event reporting, product follow-up, and fast two-way communication with physicians and regulators. That post-market oversight protects trust and keeps compliance tight, especially for long-term rare-disease treatment where safety signals can emerge after launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 approved therapies need active safety monitoring.\u003c\/li\u003e\n\u003cli\u003ePost-market follow-up supports regulator trust.\u003c\/li\u003e\n\u003cli\u003eClear communication helps detect safety signals early.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient access through partner channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients usually get Protalix BioTherapeutics, Inc. therapies through hospitals, specialists, and partner networks, not direct-to-consumer sales. That access model fits rare diseases like Fabry, which affects about 1 in 40,000 to 1 in 117,000 births, and supports channel control around specialist dosing, reimbursement, and follow-up.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eAccess runs through specialty care sites.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePartners help open reimbursement channels.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eRare-disease care favors structured pathways.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtalix Growth Hinges on Partnered Rare-Disease Commercial Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. builds customer ties through pharma licensing, hospital specialists, and payer access, with partner execution central to revenue from Elfabrio and Elelyso. Its 2 approved therapies need tight safety follow-up and medical support across rare-disease care paths.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved therapies\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFabry prevalence\u003c\/td\u003e\n\u003ctd\u003e1 in 40,000 to 1 in 117,000 births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eChannels\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner commercialization channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics uses partner commercialization channels to market and distribute key products, including Elfabrio with Chiesi and Elelyso with Pfizer, which gives it reach across many markets without building a full sales force country by country. This partner-led model is central to Protalix BioTherapeutics' international strategy and helps keep overhead lower while expanding access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and infusion centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc.'s rare-disease biologics are usually given by IV in hospitals and infusion centers, where trained staff can monitor patients during treatment. Elfabrio for Fabry disease is dosed every 2 weeks, so these sites also drive specialist follow-up and repeat visits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and public-health systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment and public-health systems are a key channel for Protalix BioTherapeutics, Inc. in Brazil and other international markets, where public buyers serve about 75% of Brazil’s population through SUS. Sales often move through tenders, formulary listings, and reimbursement, which can support large-scale access once a product is approved.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty physician networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialty physician networks are Protalix BioTherapeutics, Inc.'s key referral path: genetics, neurology, nephrology, pulmonology, and metabolic disease specialists help find rare-disease patients and shape treatment starts. In rare disease care, specialist trust matters because peer-reviewed clinical confidence drives adoption of enzyme therapies like Elfabrio and Everzol.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-value referral gatekeepers\u003c\/li\u003e\n\u003cli\u003eClinical trust lifts uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory-approved international distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProtalix BioTherapeutics sells through country-specific approvals and local distributors, so access depends on each market’s regulatory status. Its approved footprint spans the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey, tying channel reach directly to regulatory clearance and partner coverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSeven-country approved footprint\u003c\/li\u003e\n\u003cli\u003eAccess varies by local status\u003c\/li\u003e\n\u003cli\u003eDistribution is partner-led\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-Led Access Powers Protalix’s Global Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. relies on partner-led channels, especially Chiesi for Elfabrio and Pfizer for Elelyso, to reach hospitals, infusion centers, and public buyers without building a large global sales force. Its access is tied to local approvals, with a seven-country footprint and Brazil’s SUS covering about 75% of the population.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003eChiesi, Pfizer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCare sites\u003c\/td\u003e\n\u003ctd\u003eIV hospitals, infusion centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic access\u003c\/td\u003e\n\u003ctd\u003eBrazil SUS reaches 75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFootprint\u003c\/td\u003e\n\u003ctd\u003e7 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Segments\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGaucher disease patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGaucher disease patients are Protalix BioTherapeutics, Inc.’s core customer segment for Elelyso, its established enzyme replacement therapy. This is the company’s current commercial patient base, with demand tied to the rare lysosomal storage disorder’s long-term treatment needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFabry disease patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFabry disease patients are the core customer segment for Protalix BioTherapeutics, because PRX-102 targets this rare lysosomal storage disorder, which affects about 1 in 40,000 males. With only a small patient pool but high treatment value, this is one of Protalix’s key growth lanes and a major driver of future royalty and sales upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with cystic fibrosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients with cystic fibrosis are a new respiratory-care segment for Protalix BioTherapeutics, Inc., with PRX-110 aimed at airway management and chronic lung disease. The market is meaningful: cystic fibrosis affects about 105,000 people worldwide and roughly 40,000 in the U.S., so this focus broadens Protalix BioTherapeutics, Inc. beyond lysosomal storage disorders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatients with gout and NETs-related disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. serves patients with gout and NETs-related disease through PRX-115 and PRX-119, widening its reach beyond existing enzyme-replacement users. Gout affects about 4% of U.S. adults, and NETs biology is tied to high-unmet-need inflammatory disease, so these programs add specialty niches with distinct clinical and commercial upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePRX-115: gout segment\u003c\/li\u003e\n\u003cli\u003ePRX-119: NETs-related disease\u003c\/li\u003e\n\u003cli\u003eTargets specialty, unmet-need patients\u003c\/li\u003e\n\u003cli\u003eDiversifies pipeline beyond current therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHospitals, governments, and payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospitals, governments, and payers are the real gatekeepers for Protalix BioTherapeutics, Inc. In rare disease care, access depends on formulary placement, reimbursement, and public procurement, not just patient demand. Rare diseases affect fewer than 200,000 people in the U.S., so each buying decision can shape uptake fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormulary inclusion drives access\u003c\/li\u003e\n\u003cli\u003eReimbursement shapes revenue\u003c\/li\u003e\n\u003cli\u003ePublic buyers can scale volume\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtalix’s Rare-Disease Market: Small Patient Base, Big Access Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. serves a small but high-value rare-disease base: Gaucher and Fabry patients, plus adjacent specialty groups in cystic fibrosis, gout, and NETs-linked inflammation. Its real customers also include hospitals, payers, and public health systems, since access and reimbursement drive uptake in rare-disease care.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGaucher\u003c\/td\u003e\n\u003ctd\u003eElelyso base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFabry\u003c\/td\u003e\n\u003ctd\u003ePRX-102 growth lane\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCF, gout, NETs\u003c\/td\u003e\n\u003ctd\u003ePipeline expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers, hospitals\u003c\/td\u003e\n\u003ctd\u003eAccess gatekeepers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCost Structure\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and preclinical spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. must keep funding discovery, protein engineering, and lab work across multiple pipeline candidates, so R\u0026amp;D stays a core fixed and variable cost. In 2025 filings, this spend is tied to preclinical advancement, assay work, and platform upkeep, making it one of the main cash uses in the Business Model Canvas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLate-stage trials can run into tens of millions of dollars and take 1-3 years, with spend concentrated in patient recruitment, site management, data handling, and safety monitoring. For Protalix BioTherapeutics, Inc., PRX-102 and other programs keep this cost line high because Phase 3 work is the most cash-intensive part of development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and CMC expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and CMC expenses are a major cost center for Protalix BioTherapeutics, Inc. because plant-cell derived biologics need controlled production, raw materials, and lot testing to meet GMP and regulatory standards. In its latest filings, CMC spending stays central to scaling products like Elfabrio, since validation, process control, and release testing often drive a large share of biologics cash burn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory and compliance costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory and compliance costs are a permanent load for Protalix BioTherapeutics, Inc.: it must keep quality systems, pharmacovigilance, and global filings running, and U.S. FDA FY2026 user fees alone can reach $4,310,000 for a standard NDA\/BLA application. Compliance spend stays active after approval, not just at launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuality systems stay on.\u003c\/li\u003e\n\u003cli\u003eFilings repeat across markets.\u003c\/li\u003e\n\u003cli\u003eSafety reporting never stops.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSG\u0026amp;A and partnership costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSelling, general, and administrative costs fund Protalix BioTherapeutics, Inc.’s corporate overhead and commercialization work, while partnership deals add legal, contract, and coordination spend. As the company pushes more products and markets, these costs typically rise with the broader operating footprint.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCorporate overhead supports selling and admin work\u003c\/li\u003e\n\u003cli\u003ePartnerships add legal and coordination costs\u003c\/li\u003e\n\u003cli\u003eGlobal expansion usually lifts SG\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtalix Cost Structure: R\u0026amp;D, Manufacturing, and $4.31M FDA Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCost Structure for Protalix BioTherapeutics, Inc. is driven by R\u0026amp;D, biologics manufacturing, regulatory work, and SG\u0026amp;A. FDA FY2026 user fees can reach $4,310,000 for a standard NDA\/BLA, so compliance and filing costs stay meaningful even after approval.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA FY2026 NDA\/BLA fee\u003c\/td\u003e\n\u003ctd\u003e$4,310,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore spend\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D, CMC, SG\u0026amp;A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRevenue Streams\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElelyso product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElelyso is Protalix BioTherapeutics, Inc.'s main commercial revenue stream, with sales from approved markets and partner distribution deals. The product has been FDA-approved since 2012, and its recurring sales base is the clearest product income line in the model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner collaboration revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. can generate partner collaboration revenue from alliances with Pfizer, Fiocruz, and Chiesi. These deals may bring upfront cash, service fees, and shared-commercialization income, which is a key biotech funding stream because it helps offset R\u0026amp;D spend while products move toward market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMilestone payments are a non-recurring revenue line for Protalix BioTherapeutics, Inc., triggered by development or regulatory progress in partnered programs. In 2025, Protalix still relied on collaboration-driven income, with Elfabrio royalties and milestones tied to Chiesi helping monetize pipeline execution before full product scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRoyalties on partnered products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoyalties on partnered products give Protalix BioTherapeutics, Inc. high-margin income once a partnered drug reaches market, since Protalix earns a cut of partner sales without carrying full commercial cost. The stream is still tied to partner execution: if sales rise, royalties rise; if launch or uptake slows, Protalix’s revenue softens.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-margin post-launch income\u003c\/li\u003e\n\u003cli\u003ePartner sales drive royalty size\u003c\/li\u003e\n\u003cli\u003eLower cost than direct manufacturing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture pipeline commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFuture pipeline commercialization is Protalix BioTherapeutics, Inc.'s main long-term upside, with PRX-110, PRX-115, and PRX-119 as future revenue drivers and PRX-102 already broadening income beyond Elelyso through partnered commercialization. If these assets win approvals, Protalix BioTherapeutics, Inc. can move from a one-product model to a multi-asset revenue base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eElelyso is the current core product.\u003c\/li\u003e\n\u003cli\u003ePRX-102 adds partnered commercial upside.\u003c\/li\u003e\n\u003cli\u003ePRX-110, PRX-115, PRX-119 are key optionality.\u003c\/li\u003e\n\u003cli\u003eApprovals would diversify revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtalix Revenue Still Leans on Elelyso, With Pipeline Upside Growing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProtalix BioTherapeutics, Inc. earns most cash from Elelyso sales, plus partner revenue from Pfizer, Chiesi, and Fiocruz. In 2025, royalties and milestones from partnered products still mattered, while PRX-102 broadened the base beyond a single product line.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2025\/2026 note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eElelyso sales\u003c\/td\u003e\n\u003ctd\u003eCore product; FDA approved 2012\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner revenue\u003c\/td\u003e\n\u003ctd\u003eRoyalties, milestones, fees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline upside\u003c\/td\u003e\n\u003ctd\u003ePRX-102, PRX-110, PRX-115, PRX-119\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234865881353,"sku":"plx-business-model-canvas","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/plx-business-model.webp?v=1785728822","url":"https:\/\/dcfanalyst.com\/products\/plx-business-model-canvas","provider":"DCF Analyst","version":"1.0","type":"link"}